Hemoglobin variability with epoetin beta and continuous erythropoietin receptor activator in patients on peritoneal dialysis

Peritoneal Dialysis International

Volumn 32, Issue 2, 2012, Pages 177-182

  Selby, Nicholas M ^a   Fonseca, Sally A ^a   Fluck, Richard J ^a   Taal, Maarten W ^a,b  

^a ROYAL DERBY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Continuous erythropoietin receptor activator; Cycling; Erythropoietin; Hemoglobin

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSFERRIN BLOOD LEVEL;

ADULT; AGED; ANEMIA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES;

EID: 84857856320     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2010.00299     Document Type: Article

References (17)

1. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercur-rent events, and hospitalizations. Clin J am Soc Nephrol 2006; 1:1205-10.
2. Lacson E Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003; 41:111-24.
3. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005; 68:1337-43.
4. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J am Soc Nephrol 2006; 17:1181-91.
5. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ. Hemoglobin level variability: associations with mortality. Clin J am Soc Nephrol 2008; 3:133-8.
6. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339:584-90.
7. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085-98.
8. van der Putten K, van der Baan FH, Schellekens H, Gail-lard CA. Hemoglobin variability in patients with chronic kidney disease in the Netherlands. Int J artif organs 2009; 32:787-93.
9. Walker R, Pussell BA On behalf of the Australian Renal Anaemia Group. Fluctuations in haemoglobin levels in hae-modialysis, pre-dialysis and peritoneal dialysis patients receiving epoetin alpha or darbepoetin alpha. Nephrology (carlton) 2009; 14:689-95.
10. Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, et al. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Clin Ther 2007; 29:626-39.
11. Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, et al. CERA maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. am J Nephrol 2008; 28:280-9.
12. Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, et al. Once-monthly subcutaneous CERA maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J am Soc Nephrol 2007; 2:637-46.
13. Brunelli SM, Joffe MM, Israni RK, Yang W, Fishbane S, Berns JS, et al. History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J am Soc Nephrol 2008; 3:777-82.
14. Ishani A, Solid CA, Weinhandl ED, Gilbertson DT, Foley RN, Collins AJ. Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death. Nephrol Dial Transplant 2008; 23:1682-9.
15. UK Renal Association, Standards and Audit Subcommittee. Treatment of adults and children with Renal Failure: Standards and audit Measures. Guideline 2-Complications of CKD. London, UK: Royal College of Physicians of London and UK Renal Association; 2007.
16. West RM, Harris K, Gilthorpe MS, Tolman C, Will EJ. Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients describes the variability of patient responses in the control of renal anemia. J am Soc Nephrol 2007; 18:2371-6.
17. Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L, et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JaMa 2011; 305:1863-72.